A Randomized Study to Evaluate the Bioavailability of BMS-986141 From a Form B Tablet Formulation Relative to the Form A Reference Tablet in Healthy Participants
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2018
At a glance
- Drugs BMS 986141 (Primary)
- Indications Thrombosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 21 Mar 2018 Planned end date has been changed from 1 Mar 2018 to 7 Feb 2017
- 21 Mar 2018 Planned primary completion date has been changed from 1 Mar 2018 to 7 Feb 2017.
- 21 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.